Pharmesis International Ltd. provided earnings guidance for the six months ended June 30, 2023. For the six months, the company expects to report a net loss for the unaudited condensed interim financial statements for the six months ended 30 June 2023.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.081 SGD | -23.58% |
|
-23.58% | -17.35% |
06-14 | Singapore Shares Down Tracking Global Market Losses; Soilbuild Soars 147% | MT |
06-14 | Pharmesis International Completes Subscription Deal Following Share Issue; Shares Surge 32% | MT |
1st Jan change | Capi. | |
---|---|---|
-17.35% | 1.89M | |
+55.32% | 815B | |
+44.05% | 641B | |
-6.75% | 352B | |
+13.56% | 314B | |
+10.68% | 303B | |
+16.57% | 242B | |
+2.04% | 224B | |
+13.31% | 218B | |
+8.48% | 168B |
- Stock Market
- Equities
- BFK Stock
- News Pharmesis International Ltd.
- Pharmesis International Ltd. Provides Earnings Guidance for the Six Months Ended June 30, 2023